68
Participants
Start Date
December 1, 2023
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
Sintilimab
Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Fruquintinib or Regorafenib
"The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months."
Fruquintinib
Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
RECRUITING
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER